{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,29]],"date-time":"2026-05-29T09:55:09Z","timestamp":1780048509307,"version":"3.53.1"},"reference-count":57,"publisher":"Hindawi Limited","issue":"3","license":[{"start":{"date-parts":[[2016,4,5]],"date-time":"2016-04-05T00:00:00Z","timestamp":1459814400000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/doi.wiley.com\/10.1002\/tdm_license_1"},{"start":{"date-parts":[[2016,4,5]],"date-time":"2016-04-05T00:00:00Z","timestamp":1459814400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Perspect Psychiatr Care"],"published-print":{"date-parts":[[2017,7]]},"DOI":"10.1111\/ppc.12150","type":"journal-article","created":{"date-parts":[[2016,4,10]],"date-time":"2016-04-10T12:23:49Z","timestamp":1460291029000},"page":"148-155","source":"Crossref","is-referenced-by-count":13,"title":["Cariprazine for the Treatment of Bipolar Disorder"],"prefix":"10.1155","volume":"53","author":[{"given":"Lillian Jan","family":"Findlay","sequence":"first","affiliation":[{"name":"Lillian Jan Findlay, PhD, is Assistant Professor, and Coordinator, Psychiatric Mental Health Academic Program, School of Nursing; University of Kentucky; Lexington Kentucky USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peggy L.","family":"El-Mallakh","sequence":"additional","affiliation":[{"name":"Peggy L. El-Mallakh, PhD, is Assistant Professor, School of Nursing; University of Kentucky; Lexington Kentucky USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rif S.","family":"El-Mallakh","sequence":"additional","affiliation":[{"name":"Rif S. El-Mallakh, MD, Director, Mood Disorders Research Program, Department of Psychiatry and Behavioral Sciences; University of Louisville School of Medicine; Louisville Kentucky USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"98","published-online":{"date-parts":[[2016,4,5]]},"reference":[{"key":"10.1111\/ppc.12150-BIB0002|ppc12150-cit-0002","doi-asserted-by":"crossref","first-page":"3437","DOI":"10.1016\/j.bmcl.2012.03.104","article-title":"Discovery of cariprazine (RGH-188): A novel antipsychotic acting on dopamine D3\/D2 receptors","volume":"22","author":"\u00c1gaine-Csongor","year":"2012","journal-title":"Bioorganic and Medicinal Chemistry Letters"},{"key":"10.1111\/ppc.12150-BIB0003|ppc12150-cit-0003","unstructured":"Anonymous. 2014 Current Psychiatry http:\/\/www.currentpsychiatry.com\/home\/article\/cariprazine-performs-well-for-schizophrenia-bipolar-mania\/d003a3cfa939d896e7ae82c56b012a92.html"},{"issue":"2-3","key":"10.1111\/ppc.12150-BIB0004|ppc12150-cit-0004","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1016\/j.schres.2006.01.010","article-title":"Antipsychotic-induced tardive dyskinesia and the Ser9Gly polymorphism in the DRD3 gene: A meta analysis","volume":"83","author":"Bakker","year":"2006","journal-title":"Schizophrenia Research"},{"issue":"2","key":"10.1111\/ppc.12150-BIB0005|ppc12150-cit-0005","doi-asserted-by":"crossref","first-page":"501","DOI":"10.1124\/jpet.112.198895","article-title":"In vivo occupancy of dopamine D3 receptors by antagonists produces neurochemical and behavioral effects of potential relevance to attention-deficit-hyperactivity disorder","volume":"344","author":"Barth","year":"2013","journal-title":"Journal of Pharmacology and Experimental Therapeutics"},{"key":"10.1111\/ppc.12150-BIB0006|ppc12150-cit-0006","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1016\/0006-8993(91)91456-B","article-title":"Localization of dopamine D3 receptor mRNA in the rat brain using in situ hybridization histochemistry: Comparison with dopamine D2 receptor mRNA","volume":"564","author":"Bouthenet","year":"1991","journal-title":"Brain Research"},{"issue":"1","key":"10.1111\/ppc.12150-BIB0007|ppc12150-cit-0007","doi-asserted-by":"crossref","first-page":"381","DOI":"10.1124\/jpet.102.033175","article-title":"Aripiprazole, a novel antipsychotic, is a high-affinity partial agonist at human dopamine D2 receptors","volume":"302","author":"Burris","year":"2002","journal-title":"Journal of Pharmacology and Experimental Therapeutics"},{"key":"10.1111\/ppc.12150-BIB0008|ppc12150-cit-0008","doi-asserted-by":"crossref","first-page":"319","DOI":"10.2147\/TCRM.S35137","article-title":"A new generation of antipsychotics: Pharmacology and clinical utility of cariprazine in schizophrenia","volume":"9","author":"Caccia","year":"2013","journal-title":"Therapeutic Clinical Risk Management"},{"issue":"2","key":"10.1111\/ppc.12150-BIB0009|ppc12150-cit-0009","doi-asserted-by":"crossref","first-page":"114","DOI":"10.1007\/s12325-013-0006-7","article-title":"Cariprazine in schizophrenia: Clinical efficacy, tolerability, and place in therapy","volume":"30","author":"Citrome","year":"2013","journal-title":"Advances in Therapy"},{"issue":"2","key":"10.1111\/ppc.12150-BIB0010|ppc12150-cit-0010","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1517\/17425255.2013.759211","article-title":"Cariprazine: Chemistry, pharmacodynamics, pharmacokinetics, and metabolism, clinical efficacy, safety, and tolerability","volume":"9","author":"Citrome","year":"2013","journal-title":"Expert Opinion in Drug Metabolism and Toxicology"},{"key":"10.1111\/ppc.12150-BIB0011|ppc12150-cit-0011","doi-asserted-by":"crossref","first-page":"879","DOI":"10.1007\/s40263-013-0105-7","article-title":"A review of the pharmacology, efficacy and tolerability of recently approved and upcoming oral antipsychotics: An evidenced-based medicine approach","volume":"27","author":"Citrome","year":"2013c","journal-title":"CNS Drugs"},{"key":"10.1111\/ppc.12150-BIB0012|ppc12150-cit-0012","unstructured":"ClinicalTrials.gov. 2015 Cariprazine relative to placebo in the prevention of relapse of symptoms in patients with schizophrenia https:\/\/clinicaltrials.gov\/ct2\/show\/NCT01412060"},{"issue":"1-3","key":"10.1111\/ppc.12150-BIB0013|ppc12150-cit-0013","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1016\/j.ejphar.2006.01.051","article-title":"Partial agonist properties of the antipsychotics SSR181507, aripiprazole and bifeprunox at dopamine D2 receptors: G protein activation and prolactin release","volume":"535","author":"Cosi","year":"2006","journal-title":"European Journal of Pharmacology"},{"key":"10.1111\/ppc.12150-BIB0014|ppc12150-cit-0014","unstructured":"Cutler , A. Lieberman , J. Wan , S. Migliore , R. Laszlovszky , I. N\u00e9meth , G. Durgam , S. 2015 Cariprazine in acute exacerbation of schizophrenia: A fixed-dose phase iii, randomized, double-blind, placebo- and active-controlled trial http:\/\/www.psychcongress.com\/posters\/cariprazine-acute-exacerbation-schizophrenia-fixed-dose-phase-iii-randomized-double-blind"},{"key":"10.1111\/ppc.12150-BIB0015|ppc12150-cit-0015","doi-asserted-by":"crossref","first-page":"1384","DOI":"10.1111\/j.1460-9568.1994.tb00329.x","article-title":"Opposing roles for dopamine D2 and D3 receptors on neurotensin mRNA expression in nucleus accumbens","volume":"6","author":"Diaz","year":"1994","journal-title":"European Journal of Neuroscience"},{"key":"10.1111\/ppc.12150-BIB0016|ppc12150-cit-0016","doi-asserted-by":"crossref","unstructured":"Durgam , S. Nasrallah , H. A. Cutler , A. Wang , Y. Lu , K. Nagy , K. Laszlovszky , I. 2014 Safety and tolerability of cariprazine in long-term treatment of schizophrenia: Integrated summary of safety data (poster #P-05-027) http:\/\/www.prnewswire.com\/news-releases\/richter-and-actavis-announce-positive-phase-iii-results-for-cariprazine-in-the-prevention-of-relapse-in-patients-with-schizophrenia-300022547.html","DOI":"10.1016\/S0920-9964(14)70777-7"},{"key":"10.1111\/ppc.12150-BIB0017|ppc12150-cit-0017","doi-asserted-by":"crossref","first-page":"450","DOI":"10.1016\/j.schres.2013.11.041","article-title":"An evaluation of the safety and efficacy of cariprazine in patients with acute exacerbation of schizophrenia: A phase II, randomized clinical trial","volume":"152","author":"Durgam","year":"2014","journal-title":"Schizophrenia Research"},{"issue":"1","key":"10.1111\/ppc.12150-BIB0018|ppc12150-cit-0018","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1111\/bdi.12238","article-title":"The efficacy and tolerability of cariprazine in acute mania associated with bipolar I disorder: A phase II trial","volume":"17","author":"Durgam","year":"2015","journal-title":"Bipolar Disorders"},{"key":"10.1111\/ppc.12150-BIB0019|ppc12150-cit-0019","doi-asserted-by":"crossref","first-page":"189","DOI":"10.4137\/JCNSD.S4441","article-title":"Current and emerging therapies for the management of bipolar disorders","volume":"3","author":"El-Mallakh","year":"2011","journal-title":"Journal of Central Nervous System Disorders"},{"key":"10.1111\/ppc.12150-BIB0020|ppc12150-cit-0020","unstructured":"Forest Laboratories, Inc. 2010 Forest Laboratories, Inc. and Gedeon Richter Plc announce results from a phase II study of cariprazine for the treatment of bipolar depression http:\/\/news.frx.com\/press-release\/rd-news\/forest-laboratories-inc-and-gedeon-richter-plc-announce-results-phase-ii-stu-0"},{"key":"10.1111\/ppc.12150-BIB0021|ppc12150-cit-0021","unstructured":"Forest Laboratories, Inc. 2011 Forest Laboratories, Inc. and Gedeon Richter Plc announce results from a phase II study of cariprazine as adjunctive therapy in major depressive disorder http:\/\/investor.frx.com\/press-release\/rd-news\/forest-laboratories-inc-and-gedeon-richter-plc-announce-results-phase-ii-study"},{"key":"10.1111\/ppc.12150-BIB0022|ppc12150-cit-0022","unstructured":"Forest Laboratories, Inc 2012 Forest Laboratories, Inc. and Gedeon Richter Plc. announce results from two positive phase III trials with the investigational antipsychotic cariprazine for the treatment of schizophrenia http:\/\/news.frx.com\/press-release\/rd-news\/forest-laboratories-inc-and-gedeon-richter-plc-announce-results-two-positive-p"},{"key":"10.1111\/ppc.12150-BIB0023|ppc12150-cit-0023","unstructured":"Forest Laboratories, Inc 2012 Forest Laboratories, Inc. and Gedeon Richter Plc. announce of results from two phase III trials with the investigational antipsychotic cariprazine for the treatment of schizophrenia http:\/\/news.frx.com\/press-release\/rd-news\/forest-laboratories-inc-and-gedeon-richter-plc-announce-results-two-positive-p"},{"key":"10.1111\/ppc.12150-BIB0024|ppc12150-cit-0024","unstructured":"Forest Laboratories, Inc. 2014a Forest Laboratories, Inc. and Gedeon Richter Plc. announce positive phase IIb topline results for cariprazine for the treatment of bipolar depression http:\/\/investor.frx.com\/press-release\/r-and-d-news\/forest-laboratories-inc-and-gedeon-richter-plc-announce-positive-phase-0"},{"key":"10.1111\/ppc.12150-BIB0025|ppc12150-cit-0025","unstructured":"Forest Laboratories, Inc. 2014b Forest Laboratories, Inc. and Gedeon Richter Plc. announce positive phase IIb topline results for cariprazine as adjunctive therapy in the treatment of major depressive disorder http:\/\/investor.frx.com\/press-release\/r-and-d-news\/forest-laboratories-inc-and-gedeon-richter-plc-announce-positive-phase-ii"},{"issue":"3","key":"10.1111\/ppc.12150-BIB0026|ppc12150-cit-0026","doi-asserted-by":"crossref","first-page":"222","DOI":"10.1016\/j.jad.2011.04.043","article-title":"Receptor targets for antidepressant therapy in bipolar disorder: An overview","volume":"138","author":"Fountoulakis","year":"2012","journal-title":"Journal of Affective Disorders"},{"issue":"1","key":"10.1111\/ppc.12150-BIB0027|ppc12150-cit-0027","doi-asserted-by":"crossref","first-page":"e00073","DOI":"10.1002\/prp2.73","article-title":"Cariprazine exerts antimanic properties and interferes with dopamine D2 receptor \u00df-arrestin interactions","volume":"3","author":"Gao","year":"2015","journal-title":"Pharmacology Research Perspectives"},{"key":"10.1111\/ppc.12150-BIB0028|ppc12150-cit-0028","doi-asserted-by":"crossref","first-page":"1497","DOI":"10.1007\/s00228-013-1498-4","article-title":"Newer antipsychotics and upcoming molecules for schizophrenia","volume":"69","author":"George","year":"2013","journal-title":"European Journal of Clinical Pharmacology"},{"issue":"2","key":"10.1111\/ppc.12150-BIB0029|ppc12150-cit-0029","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1007\/s00210-012-0806-3","article-title":"Dopamine D\u2083 receptor antagonism - Still a therapeutic option for the treatment of schizophrenia","volume":"386","author":"Gross","year":"2013","journal-title":"Naunyn Schmiedeberg's Archives of Pharmacology"},{"issue":"Suppl. 1","key":"10.1111\/ppc.12150-BIB0030|ppc12150-cit-0030","doi-asserted-by":"crossref","first-page":"S21","DOI":"10.1055\/s-2006-931485","article-title":"Aripiprazole: Pharmacodynamics of a dopamine partial agonist for the treatment of schizophrenia","volume":"39","author":"Gr\u00fcnder","year":"2006","journal-title":"Pharmacopsychiatry"},{"issue":"6","key":"10.1111\/ppc.12150-BIB0031|ppc12150-cit-0031","doi-asserted-by":"crossref","first-page":"925","DOI":"10.1016\/j.neuint.2011.07.002","article-title":"Cariprazine (RGH-188), a potent D3\/D2 dopamine receptor partial agonist, binds to dopamine D3 receptors in vivo and shows antipsychotic-like and procognitive effects in rodents","volume":"59","author":"Gyerty\u00e1n","year":"2011","journal-title":"Neurochemistry International"},{"issue":"5","key":"10.1111\/ppc.12150-BIB0032|ppc12150-cit-0032","doi-asserted-by":"crossref","first-page":"389","DOI":"10.2165\/00023210-200620050-00004","article-title":"Mechanism of action of atypical antipsychotic drugs and the neurobiology of schizophrenia","volume":"20","author":"Horacek","year":"2006","journal-title":"CNS Drugs"},{"key":"10.1111\/ppc.12150-BIB0033|ppc12150-cit-0033","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1007\/s40501-014-0010-9","article-title":"Current and emergent treatments for symptoms and neurocognitive impairment in schizophrenia","volume":"1","author":"Javitt","year":"2015","journal-title":"Current Treatment Options in Psychiatry"},{"issue":"10","key":"10.1111\/ppc.12150-BIB0034|ppc12150-cit-0034","doi-asserted-by":"crossref","first-page":"2605","DOI":"10.1007\/s11095-014-1358-7","article-title":"Dopamine D2 receptor occupancy as a predictor of catalepsy in rats: A pharmacokinetic-pharmacodynamic modeling approach","volume":"31","author":"Johnson","year":"2014","journal-title":"Pharmacy Research"},{"issue":"Suppl. 4","key":"10.1111\/ppc.12150-BIB0035|ppc12150-cit-0035","doi-asserted-by":"crossref","first-page":"S433","DOI":"10.1016\/S0924-977X(08)70635-7","article-title":"(P.3.c.051) Comparison of the pharmacokinetic behaviour of RGH-188 in schizophrenic patients and healthy volunteers","volume":"18","author":"Kap\u00e1s","year":"2008","journal-title":"European Neuropsychopharmacology"},{"issue":"7","key":"10.1111\/ppc.12150-BIB0036|ppc12150-cit-0036","doi-asserted-by":"crossref","first-page":"948","DOI":"10.1176\/ajp.153.7.948","article-title":"High levels of dopamine D-2 receptor occupancy with low-dose haloperidol treatment: A PET study","volume":"153","author":"Kapur","year":"1996","journal-title":"American Journal of Psychiatry"},{"issue":"2","key":"10.1111\/ppc.12150-BIB0037|ppc12150-cit-0037","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1007\/s002130050277","article-title":"The relationship between D2 receptor occupancy and plasma levels on low dose oral haloperidol: A PET study","volume":"131","author":"Kapur","year":"1997","journal-title":"Psychopharmacology (Berlin)"},{"key":"10.1111\/ppc.12150-BIB0038|ppc12150-cit-0038","unstructured":"Kirschner , N. G\u00e9mesi , L. I. Vastag , M. \u00c1gaine-Csongor , \u00c9. Dom\u00e1ny , G. Kap\u00e1s , M. Tihany , K. 2008 In vitro metabolism of RGH-188 https:\/\/issx.confex.com\/issx\/10euro\/webprogram\/Paper8686.html"},{"issue":"1","key":"10.1111\/ppc.12150-BIB0039|ppc12150-cit-0039","doi-asserted-by":"crossref","first-page":"328","DOI":"10.1124\/jpet.109.160432","article-title":"Cariprazine (RGH-188), a dopamine D3 receptor-preferring, D3\/D2 dopamine receptor antagonist-partial agonist antipsychotic candidate: In vitro and neurochemical profile","volume":"333","author":"Kiss","year":"2010","journal-title":"Journal of Pharmacology and Experimental Therapeutics"},{"issue":"Suppl. 4","key":"10.1111\/ppc.12150-BIB0040|ppc12150-cit-0040","doi-asserted-by":"crossref","first-page":"S455","DOI":"10.1016\/S0924-977X(07)70690-9","article-title":"(P.3.c.053) Dopamine D2\/D3 receptor occupancy of RGH-188, a D3\/D2 antagonist\/partial agonist antipsychotic, in healthy volunteers","volume":"17","author":"Laszlovsky","year":"2007","journal-title":"European Neuropsychopharmacology"},{"issue":"2","key":"10.1111\/ppc.12150-BIB0041|ppc12150-cit-0041","doi-asserted-by":"crossref","first-page":"314","DOI":"10.1093\/schbul\/sbu001","article-title":"Dose equivalents for second-generation antipsychotics: The minimum effective dose method","volume":"40","author":"Leucht","year":"2014","journal-title":"Schizophrenia Bulletin"},{"key":"10.1111\/ppc.12150-BIB0042|ppc12150-cit-0042","doi-asserted-by":"crossref","first-page":"S477","DOI":"10.1016\/S0924-977X(13)70756-9","article-title":"Cariprazine in acute exacerbation of schizophrenia: A fixed-dose randomised, double-blind, placebo-and-active-controlled trial","volume":"23","author":"Lieberman","year":"2013","journal-title":"European Neuropsychopharmacology"},{"key":"10.1111\/ppc.12150-BIB0043|ppc12150-cit-0043","unstructured":"Litman , R. Papadakis , K. Durgam , S. Xie , J. 2008"},{"issue":"1","key":"10.1111\/ppc.12150-BIB0044|ppc12150-cit-0044","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1080\/0964704X.2012.678199","article-title":"History of the discovery of the antipsychotic dopamine D2 receptor: A basis for the dopamine hypothesis of schizophrenia","volume":"22","author":"Madras","year":"2013","journal-title":"Journal of the History of Neuroscience"},{"issue":"4","key":"10.1111\/ppc.12150-BIB0045|ppc12150-cit-0045","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1016\/0006-3223(93)90288-O","article-title":"Central D2-dopamine receptor occupancy in relation to antipsychotic drug effects - A double-blind PET study of schizophrenic-patients","volume":"33","author":"Nordstrom","year":"1993","journal-title":"Biological Psychiatry"},{"issue":"5-6","key":"10.1111\/ppc.12150-BIB0046|ppc12150-cit-0046","doi-asserted-by":"crossref","first-page":"567","DOI":"10.1097\/FBP.0000000000000070","article-title":"Attenuation of anhedonia by cariprazine in the chronic mild stress model of depression","volume":"25","author":"Papp","year":"2014","journal-title":"Behavioural Pharmacology"},{"issue":"2","key":"10.1111\/ppc.12150-BIB0047|ppc12150-cit-0047","doi-asserted-by":"crossref","first-page":"388","DOI":"10.1016\/j.jpba.2007.12.016","article-title":"Sensitive LC-MS\/MS methods for the quantification of RGH-188 and its active metabolites, desmethyl- and didesmethyl-cariprazine in human plasma and urine","volume":"48","author":"P\u00e1sztor M\u00e9sz\u00e1ros","year":"2008","journal-title":"Journal of Pharmaceutical and Biomedical Analysis"},{"issue":"Suppl. 4","key":"10.1111\/ppc.12150-BIB0048|ppc12150-cit-0048","doi-asserted-by":"crossref","first-page":"S451","DOI":"10.1016\/S0924-977X(07)70684-3","article-title":"(P.3.c.047) Pharmacokinetics of RGH-188, a new dopamine D3\/D2 antagonist\/partial agonist atypical antipsychotic, in healthy subjects","volume":"17","author":"P\u00e1sztor M\u00e9sz\u00e1ros","year":"2007","journal-title":"European Neuropsychopharmacology"},{"issue":"Suppl. 3","key":"10.1111\/ppc.12150-BIB0049|ppc12150-cit-0049","doi-asserted-by":"crossref","first-page":"S316","DOI":"10.1016\/S0924-977X(09)70472-9","article-title":"(P.1.e.028) Dopamine D3 and D2 receptor occupancy of cariprazine in schizophrenic patients","volume":"19","author":"Potkin","year":"2009","journal-title":"European Neuropsychopharmacology"},{"key":"10.1111\/ppc.12150-BIB0050|ppc12150-cit-0050","doi-asserted-by":"crossref","first-page":"1676","DOI":"10.1046\/j.1460-9568.1998.00173.x","article-title":"Coexpression of dopamine D1 and D3 receptors in islands of Calleja and shell of nucleus accumbens of the rat: Opposite and synergistic functional interactions","volume":"10","author":"Ridray","year":"1998","journal-title":"European Journal of Neuroscience"},{"key":"10.1111\/ppc.12150-BIB0051|ppc12150-cit-0051","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1177\/070674370204700106","article-title":"Atypical antipsychotics: Mechanism of action","volume":"47","author":"Seeman","year":"2002","journal-title":"Canadian Journal of Psychiatry"},{"issue":"1-3","key":"10.1111\/ppc.12150-BIB0052|ppc12150-cit-0052","first-page":"45","article-title":"The role of tonic and phasic dopamine for long-term synaptic plasticity in the prefrontal cortex: A computational model","volume":"105","author":"Sheynikhovich","year":"2011","journal-title":"Journal of Physiology Paris"},{"key":"10.1111\/ppc.12150-BIB0054|ppc12150-cit-0054","doi-asserted-by":"crossref","first-page":"278","DOI":"10.1111\/j.1749-6632.1995.tb17486.x","article-title":"Novel dopamine receptor subtypes as targets for antipsychotic drugs","volume":"757","author":"Sokoloff","year":"1995","journal-title":"Annals of the New York Academy of Sciences"},{"key":"10.1111\/ppc.12150-BIB0055|ppc12150-cit-0055","doi-asserted-by":"crossref","first-page":"146","DOI":"10.1038\/347146a0","article-title":"Molecular cloning and characterization of a novel dopamine receptor (D3) as a target for neuroleptics","volume":"347","author":"Sokoloff","year":"1990","journal-title":"Nature"},{"issue":"1","key":"10.1111\/ppc.12150-BIB0056|ppc12150-cit-0056","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1097\/jcp.0b013e3181618eb4","article-title":"Aripiprazole monotherapy in nonpsychotic bipolar I depression: Results of 2 randomized, placebo-controlled studies","volume":"28","author":"Thase","year":"2008","journal-title":"Journal of Clinical Psychopharmacology"},{"issue":"2","key":"10.1111\/ppc.12150-BIB0057|ppc12150-cit-0057","doi-asserted-by":"crossref","first-page":"248","DOI":"10.1016\/S0893-133X(02)00304-4","article-title":"Dopamine D2 and D3 receptor occupancy in normal humans treated with the antipsychotic drug aripiprazole (OPC 14597): A study using positron emission tomography and [11C]raclopride","volume":"27","author":"Yokoi","year":"2002","journal-title":"Neuropsychopharmacology"},{"issue":"1","key":"10.1111\/ppc.12150-BIB0058|ppc12150-cit-0058","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1007\/s00213-012-2896-5","article-title":"Cariprazine, a dopamine D3-receptor-preferring partial agonist, blocks phencyclidine-induced impairments of working memory, attention set-shifting, and recognition memory in the mouse","volume":"226","author":"Zimnisky","year":"2013","journal-title":"Psychopharmacology (Berlin)"},{"issue":"S1","key":"10.1111\/ppc.12150-BIB0059|ppc12150-cit-0059","first-page":"S319","article-title":"Efficacy and safety of cariprazine in acute exacerbation of schizophrenia: A phase III, international, randomized, double-blind, placebo-controlled trial","volume":"38","author":"Zukin","year":"2012","journal-title":"Neuropsychopharmacology"}],"container-title":["Perspectives in Psychiatric Care"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fppc.12150","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fppc.12150","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/onlinelibrary.wiley.com\/wol1\/doi\/10.1111\/ppc.12150\/fullpdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,12,20]],"date-time":"2022-12-20T13:17:09Z","timestamp":1671542229000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/ppc.12150"}},"subtitle":["Cariprazine for the Treatment of Bipolar Disorder"],"short-title":[],"issued":{"date-parts":[[2016,4,5]]},"references-count":57,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2017,7]]}},"URL":"https:\/\/doi.org\/10.1111\/ppc.12150","archive":["Portico"],"relation":{},"ISSN":["0031-5990"],"issn-type":[{"value":"0031-5990","type":"print"}],"subject":[],"published":{"date-parts":[[2016,4,5]]}}}